Leon-Nanodrugs Appoints CEO
This article was originally published in Scrip
Leon-Nanodrugs, a nanotechnology-based drug development company, has named Theron Odlaug CEO of Leon-Nanodrugs GmbH. in Germany and Leon-Nanodrugs, Inc in the US. Odlaug has more than 35 years of experience in the biopharmaceutical industry and joins Leon-Nanodrugs from Cedarburg Pharmaceuticals where he was executive chair. Previously, he was the executive chair and CEO of Planet Biopharmaceuticals and CEO of CyDex Pharmaceuticals, Inc.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.